Related Experiment Videos
[The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple
1Department of Hematology and Oncology, Affiliated Beijing Chaoyang Hospital of Capital University of Medical Sciences, Beijing 100020, China. gaowenpingping@sohu.com
Objective:
To investigate the effect of the combination of thalidomide, cyclophosphamide and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Methods:
20 relapsed/refractory multiple myeloma patients received thalidomide (200 mg/d), cyclophosphamide (300 mg.m(-2).d(-1), d1-4, every 4 weeks) and pulsed dexamethasone (20-40 mg/d, d1-4, every 4 weeks).
Results:
After 3 cycles of therapy, 9 cases obtained partial remission (PR), 4 had minimal responses (MR), 5 were of no change and 2 had progressive disease. After 6 cycles of therapy, 13 patients achieved PR and 5 had MR.
Conclusion:
The combination of thalidomide, cyclophosphamide and dexamethasone is a promising treatment regime for relapsed/refractory multiple myeloma.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Therapeutic Drug Monitoring: Affecting Factors
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Treatment Resistant Cancers